QVIDTVM Management LLC Has $34.67 Million Stock Holdings in Solventum Co. (NYSE:SOLV)

QVIDTVM Management LLC grew its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 497,276 shares of the company's stock after buying an additional 59,059 shares during the period. Solventum accounts for 24.3% of QVIDTVM Management LLC's investment portfolio, making the stock its 2nd largest position. QVIDTVM Management LLC owned about 0.29% of Solventum worth $34,670,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its holdings in Solventum by 37.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company's stock valued at $8,217,000 after acquiring an additional 32,051 shares during the period. Bank of Montreal Can boosted its stake in Solventum by 15.8% in the 3rd quarter. Bank of Montreal Can now owns 182,748 shares of the company's stock worth $12,348,000 after purchasing an additional 25,002 shares during the period. Douglass Winthrop Advisors LLC purchased a new position in Solventum during the 3rd quarter valued at about $250,000. Daiwa Securities Group Inc. increased its position in shares of Solventum by 12.2% during the third quarter. Daiwa Securities Group Inc. now owns 17,623 shares of the company's stock valued at $1,229,000 after buying an additional 1,919 shares during the period. Finally, Centaurus Financial Inc. purchased a new stake in shares of Solventum in the third quarter worth about $321,000.

Solventum Price Performance

SOLV traded down $0.12 on Tuesday, hitting $71.49. 675,290 shares of the company were exchanged, compared to its average volume of 1,699,889. The firm has a fifty day simple moving average of $70.52 and a two-hundred day simple moving average of $62.35. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wolfe Research assumed coverage on Solventum in a research report on Thursday, September 26th. They issued a "peer perform" rating on the stock. Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. The Goldman Sachs Group upped their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a "sell" rating in a research report on Monday, August 12th. Wells Fargo & Company dropped their target price on shares of Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a research report on Friday, August 9th. Finally, Stifel Nicolaus assumed coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.